Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
19 participants
INTERVENTIONAL
2012-02-29
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Factors affecting the activity of carboxylesterases would be expected to markedly alter the pharmacokinetics and clinical effects of substrate drugs. One key factor that could affect catalytic activity is drug interactions that inhibit carboxylesterase function. The importance of inhibition of drug metabolism in medication safety and efficacy is well established for drugs that undergo metabolism by cytochrome P450 enzymes. In distinct contrast, little is known about the potential for carboxylesterases to serve as a target for metabolic inhibition mediated by drug interactions.
It is well established that ethanol is an inhibitor of cocaine metabolism, a drug that is eliminated by carboxylesterase hydrolysis. We propose that the ethanol-mediated inhibition of carboxylesterases activity demonstrated with cocaine metabolism will occur with other substrate drugs. This has widespread implications because of the large number of drugs that are carboxylesterase substrates. In the United States, over 100 million people consume ethanol making co-ingestion with carboxylesterase substrate drugs a common occurrence. We believe that this is a prevalent drug interaction that is largely overlooked and has not been systematically evaluated, but may importantly affect the disposition, safety, and efficacy of these medications. To address this gap, we will evaluate the effect of ethanol on the disposition of oseltamivir, an hCE1 substrate, and aspirin, an hCE2 substrate, in humans.
Normal healthy volunteers will report to the University of Tennessee Health Science Center Clinical Research Center (CRC) for a 10 hour stay on four separate days and receive each of the following treatments in random order:
1. Oseltamivir (Tamiflu®) 150 mg. Subjects will drink orange juice (about 10 ounces although the amount may vary slightly based on weight) over 15 minutes. Fifteen minutes after drinking the orange juice, subjects will receive two (2) 75 mg capsules of oseltamivir with 5 ounces of water. Blood samples (1 teaspoonful) to determine the amount of oseltamivir in blood will be collected before the dose and 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, and 24 hours hours after the dose. Subjects will be allowed to leave the CRC after the 10 hour blood sample is collected and return the following day for the 24 hour sample.
2. Oseltamivir (Tamiflu®) 150 mg + Ethanol. In this phase, subjects will drink the same amount of orange juice over 15 minutes that will now have ethanol (alcohol) added. The amount of ethanol that will be added is calculated to achieve a blood alcohol concentration of 0.08 g/dl, which is considered to be legally intoxicated. Fifteen minutes after drinking the orange juice + ethanol, subjects will receive two (2) 75 mg capsules of oseltamivir with 5 ounces of water. Blood samples will be collected at the same times as above. An additional blood sample (1 teaspoonful) for determining the blood alcohol concentration will be collected 30 minutes after drinking the orange juice + ethanol.
3. Aspirin 650 mg. Subjects will drink orange juice (about 10 ounces although the amount may vary slightly based on your weight) over 15 minutes. Fifteen minutes after drinking the orange juice, they will take two (2) 325 mg aspirin tablets with 5 oz of water. Blood samples to determine the amount of aspirin in the blood will be collected before the aspirin dose and at 10, 20, and 30 minutes after the dose and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, and 8.0 hours after the dose.
4. Aspirin 650 mg + Ethanol. In this phase, subjects will drink the same amount of orange juice over 15 minutes that will now have ethanol (alcohol) added. The amount of ethanol that will be added is calculated to achieve a blood alcohol concentration of 0.08 g/dl, which is considered to be legally intoxicated. Fifteen minutes after drinking the orange juice + ethanol, subjects will take two (2) 325 mg aspirin tablets with 5 ounces of water. Blood samples (1 teaspoonful) to determine the amount of aspirin in the blood will be collected before the aspirin dose and at 10, 20, and 30 minutes after the dose and at 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 7.0, and 8.0 hours after the dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oseltamivir & Placebo
Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
Placebo
Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
Oseltamivir
Oseltamivir 150 mg orally
Oseltamivir & Ethanol
Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
Ethanol
Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
Oseltamivir
Oseltamivir 150 mg orally
Aspirin & Placebo
Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
Placebo
Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
Aspirin
Aspirin 650 mg orally will be given
Aspirin & Ethanol
Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
Ethanol
Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
Aspirin
Aspirin 650 mg orally will be given
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
Ethanol
Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
Oseltamivir
Oseltamivir 150 mg orally
Aspirin
Aspirin 650 mg orally will be given
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* social ethanol drinker
Exclusion Criteria
* concomitant medication treatment (either prescription, over the counter, herbals, or supplements such as vitamins
* co-existing diseases affecting cardiovascular, hepatic, renal, pulmonary, hematologic, or gastrointestinal function
* platelet count \< 100,000, hematocrit \< 30
* chronic psychiatric disorder
* score \>2 on the Michigan Alcohol Screening Test (MAST)
* naive to alcohol ingestion, have a family history of alcohol dependence, or history of adverse responses to alcohol
* women with known pregnancy, lactation, or not using and effective method of birth control (subjects taking oral contraceptives will be excluded)
* ingestion of alcohol or caffeine during the study
* participation in another drug study or blood donation within the preceding weeks.
21 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tennessee
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robbie Parker
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert B Parker, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee
Steven C Laizure, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tennessee Health Science Center
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.